Patient characteristics at first visit during second-year follow-up postdiagnosis
| Number of patients | 165 |
| Age | 57.3 (13.7)* |
| Female | 59% |
| Rheumatoid factor positive | 60% |
| Disease duration in months | 12.5 (11.8–13.2)† |
| DAS28 | 3.0 (1.1)* |
| PROM score | 32 (24)* |
| Receiving DMARD | 78% (Methotrexate)‡ |
| Receiving biologic | 13% (Adalimumab)‡ |
*Mean (SD).
†Median (IQR).
‡Most prevalent agent.
DAS28, Disease Activity Score 28-joint count; DMARD, disease-modifying antirheumatic drug; PROM score, patient-reported outcome measure score consisting of an equally weighted mean of visual analogue scales for general health, pain and disease activity.